Is Sumitomo Pharma Co., Ltd. (DNPUF) a Buy, Sell, or Hold?
OTC : DNPUF
Sumitomo Pharma Co., Ltd. — News
$8.41 USD
$0 (0.0%)
- Volume
- 118
- Average Volume
- 126
- Market Capitalization
- $3.77B
- P/E Ratio
- 4.85
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $19.20
- Year Low
- $7.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.03
| Source | Headline |
|---|---|
|
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective menin inhibitor for the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement, to allow for interim analysis. Achieving this milestone will enable SMPA to obtain results of the interim analysis by the end of calendar year 2026. These results. businesswire.com - 2026-06-10 12:00:00 |
